Telomir Pharmaceuticals, Inc.
TELO
$1.26
-$0.03-2.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 116.67% | -92.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 86.19% | -77.39% | |||
| Operating Income | -86.19% | 77.39% | |||
| Income Before Tax | -86.99% | 78.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -86.99% | 78.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.99% | 78.26% | |||
| EBIT | -86.19% | 77.39% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -80.88% | 79.87% | |||
| Normalized Basic EPS | -80.75% | 79.83% | |||
| EPS Diluted | -80.88% | 79.87% | |||
| Normalized Diluted EPS | -80.75% | 79.83% | |||
| Average Basic Shares Outstanding | 3.38% | 7.96% | |||
| Average Diluted Shares Outstanding | 3.38% | 7.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||